Cash Equivalents - Genovis AB (STO:GENO) - Alpha Spread
G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 22.75 SEK 0.22%
Market Cap: 1.5B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genovis AB
Cash Equivalents Peer Comparison

Comparables:
ALIF B
BICO
BIOT
MCAP
M
MAGLE

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Cash Equivalents
kr135.8m
CAGR 3-Years
48%
CAGR 5-Years
72%
CAGR 10-Years
41%
AddLife AB
STO:ALIF B
Cash Equivalents
kr272m
CAGR 3-Years
8%
CAGR 5-Years
35%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Cash Equivalents
kr861m
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Cash Equivalents
kr318m
CAGR 3-Years
5%
CAGR 5-Years
24%
CAGR 10-Years
17%
MedCap AB (publ)
STO:MCAP
Cash Equivalents
kr262.8m
CAGR 3-Years
24%
CAGR 5-Years
71%
CAGR 10-Years
14%
M
Magle Chemoswed Holding AB
STO:MAGLE
Cash Equivalents
kr7.1m
CAGR 3-Years
5%
CAGR 5-Years
26%
CAGR 10-Years
N/A

See Also

What is Genovis AB's Cash Equivalents?
Cash Equivalents
135.8m SEK

Based on the financial report for Jun 30, 2024, Genovis AB's Cash Equivalents amounts to 135.8m SEK.

What is Genovis AB's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
41%

Over the last year, the Cash Equivalents growth was 19%. The average annual Cash Equivalents growth rates for Genovis AB have been 48% over the past three years , 72% over the past five years , and 41% over the past ten years .

Back to Top